Medicamen Biotech Share Price

Medicamen Biotech Investment Rating

• Master Rating:

• Medicamen Biotech has an operating revenue of Rs. 121.00 Cr. on a trailing 12-month basis. An annual revenue growth of 3% is not great, Pre-tax margin of 16% is great, ROE of 10% is good. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 27% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 13% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 56 which is a POOR score indicating inconsistency in earnings, a RS Rating of 82 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 124 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.